150 related articles for article (PubMed ID: 15793153)
1. Antibiotic tolerance induced by lactoferrin in clinical Pseudomonas aeruginosa isolates from cystic fibrosis patients.
Andrés MT; Viejo-Diaz M; Pérez F; Fierro JF
Antimicrob Agents Chemother; 2005 Apr; 49(4):1613-6. PubMed ID: 15793153
[TBL] [Abstract][Full Text] [Related]
2. Resistance to tobramycin and colistin in isolates of Pseudomonas aeruginosa from chronically colonized patients with cystic fibrosis under antimicrobial treatment.
Valenza G; Radike K; Schoen C; Horn S; Oesterlein A; Frosch M; Abele-Horn M; Hebestreit H
Scand J Infect Dis; 2010 Dec; 42(11-12):885-9. PubMed ID: 20735333
[TBL] [Abstract][Full Text] [Related]
3. Routine susceptibility tests with ticarcillin and tobramycin in combination should be more appropriate than with each antibiotic alone in cystic fibrosis Pseudomonas aeruginosa.
Lapointe JR; Bourget C; Mainville S; Lafleur L; Lagacé J; Montplaisir S
J Chemother; 1989 Jul; 1(4 Suppl):184-6. PubMed ID: 16312360
[No Abstract] [Full Text] [Related]
4. Aminoglycoside-resistance mechanisms for cystic fibrosis Pseudomonas aeruginosa isolates are unchanged by long-term, intermittent, inhaled tobramycin treatment.
MacLeod DL; Nelson LE; Shawar RM; Lin BB; Lockwood LG; Dirk JE; Miller GH; Burns JL; Garber RL
J Infect Dis; 2000 Mar; 181(3):1180-4. PubMed ID: 10720551
[TBL] [Abstract][Full Text] [Related]
5. Development of a rapid colorimetric time-kill assay for determining the in vitro activity of ceftazidime and tobramycin in combination against Pseudomonas aeruginosa.
Moriarty F; Elborn S; Tunney M
J Microbiol Methods; 2005 May; 61(2):171-9. PubMed ID: 15722142
[TBL] [Abstract][Full Text] [Related]
6. Effect of chronic intermittent administration of inhaled tobramycin on respiratory microbial flora in patients with cystic fibrosis.
Burns JL; Van Dalfsen JM; Shawar RM; Otto KL; Garber RL; Quan JM; Montgomery AB; Albers GM; Ramsey BW; Smith AL
J Infect Dis; 1999 May; 179(5):1190-6. PubMed ID: 10191222
[TBL] [Abstract][Full Text] [Related]
7. [In vitro bactericidal activity of tobramycin and amikacin alone or in combination against Pseudomonas aeruginosa isolated from patients with cystic fibrosis].
Bertrou A; Marty N; Henry S; Agueda L; Chabanon G
Pathol Biol (Paris); 1990 May; 38(5):366-75. PubMed ID: 2114606
[TBL] [Abstract][Full Text] [Related]
8. Multiple combination bactericidal antibiotic testing for patients with cystic fibrosis infected with multiresistant strains of Pseudomonas aeruginosa.
Lang BJ; Aaron SD; Ferris W; Hebert PC; MacDonald NE
Am J Respir Crit Care Med; 2000 Dec; 162(6):2241-5. PubMed ID: 11112146
[TBL] [Abstract][Full Text] [Related]
9. An Antipersister Strategy for Treatment of Chronic Pseudomonas aeruginosa Infections.
Koeva M; Gutu AD; Hebert W; Wager JD; Yonker LM; O'Toole GA; Ausubel FM; Moskowitz SM; Joseph-McCarthy D
Antimicrob Agents Chemother; 2017 Dec; 61(12):. PubMed ID: 28923873
[TBL] [Abstract][Full Text] [Related]
10. Antimicrobial activity of fosfomycin and tobramycin in combination against cystic fibrosis pathogens under aerobic and anaerobic conditions.
McCaughey G; McKevitt M; Elborn JS; Tunney MM
J Cyst Fibros; 2012 May; 11(3):163-72. PubMed ID: 22138067
[TBL] [Abstract][Full Text] [Related]
11. Effect of oxygen limitation on the in vitro antimicrobial susceptibility of clinical isolates of Pseudomonas aeruginosa grown planktonically and as biofilms.
Field TR; White A; Elborn JS; Tunney MM
Eur J Clin Microbiol Infect Dis; 2005 Oct; 24(10):677-87. PubMed ID: 16249934
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of the E test for the assessment of synergy of antibiotic combinations against multiresistant Pseudomonas aeruginosa isolates from cystic fibrosis patients.
Balke B; Hogardt M; Schmoldt S; Hoy L; Weissbrodt H; Häussler S
Eur J Clin Microbiol Infect Dis; 2006 Jan; 25(1):25-30. PubMed ID: 16402226
[TBL] [Abstract][Full Text] [Related]
13. Characterization of clonal strains of Pseudomonas aeruginosa isolated from cystic fibrosis patients in Ontario, Canada.
Beaudoin T; Aaron SD; Giesbrecht-Lewis T; Vandemheen K; Mah TF
Can J Microbiol; 2010 Jul; 56(7):548-57. PubMed ID: 20651854
[TBL] [Abstract][Full Text] [Related]
14. Evaluation of long-term co-administration of tobramycin and clarithromycin in a mature biofilm model of cystic fibrosis clinical isolates of Pseudomonas aeruginosa.
Tré-Hardy M; Traore H; El Manssouri N; Vanderbist F; Vaneechoutte M; Devleeschouwer MJ
Int J Antimicrob Agents; 2009 Oct; 34(4):370-4. PubMed ID: 19505804
[TBL] [Abstract][Full Text] [Related]
15. [Investigation of biofilm formation and relationship with genotype and antibiotic susceptibility of Pseudomonas aeruginosa strains isolated from patients with cystic fibrosis].
Coban AY; Ciftci A; Onuk EE; Erturan Z; Tanriverdi Cayci Y; Durupinar B
Mikrobiyol Bul; 2009 Oct; 43(4):563-73. PubMed ID: 20084909
[TBL] [Abstract][Full Text] [Related]
16. In vitro interactions of tobramycin with various nonantibiotics against Pseudomonas aeruginosa and Burkholderia cenocepacia.
Treerat P; Widmer F; Middleton PG; Iredell J; George AM
FEMS Microbiol Lett; 2008 Aug; 285(1):40-50. PubMed ID: 18513356
[TBL] [Abstract][Full Text] [Related]
17. Ability of azlocillin and tobramycin in combination to delay or prevent resistance development in Pseudomonas aeruginosa.
Wu YL; Scott EM; Po AL; Tariq VN
J Antimicrob Chemother; 1999 Sep; 44(3):389-92. PubMed ID: 10511408
[TBL] [Abstract][Full Text] [Related]
18. Consequences of combining cystic fibrosis- and non-cystic fibrosis-derived Pseudomonas aeruginosa antibiotic susceptibility results in hospital antibiograms.
Bosso JA; Mauldin PD; Steed LL
Ann Pharmacother; 2006 Nov; 40(11):1946-9. PubMed ID: 17018687
[TBL] [Abstract][Full Text] [Related]
19. Development of resistance and cross-resistance in Pseudomonas aeruginosa exposed to subinhibitory antibiotic concentrations.
Wu YL; Scott EM; Po AL; Tariq VN
APMIS; 1999 Jun; 107(6):585-92. PubMed ID: 10379686
[TBL] [Abstract][Full Text] [Related]
20. In vitro activity of antibiotic combinations against Pseudomonas aeruginosa biofilm and planktonic cultures.
Tré-Hardy M; Vanderbist F; Traore H; Devleeschouwer MJ
Int J Antimicrob Agents; 2008 Apr; 31(4):329-36. PubMed ID: 18280117
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]